Figure 4.
ZIKV infection does not antagonize type I IFN-mediated responses in MDMs. (A) Schematic illustration of human recombinant IFN-α treatment and ZIKV infection. (B) MDMs and moDCs were uninfected or infected with ZIKVPR at an MOI of 10.0 for 6 h, followed by mock treatment or treatment with 1000U/mL of recombinant human IFN-α for 6 h. Cell lysates were collected for detection of ISGs induction using qRT-PCR, including IFIT1, ISG15, MX1, and PKR; the fold activations were calculated as compared to mock groups. Data represented mean and standard deviations from 3 donors. Statistical analyses in all panels were performed with one way-ANOVA and the differences were considered significant when p < 0.05. **p < 0.01, ***p < 0.001, and ****p < 0.0001. ns, not significant.